Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KA
- Price
- 0.48
- Stock movement down
- -0.04 (-8.08%)
- Company name
- Kineta Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.89M
- Ent value
- 14.29M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -84.76%
- 3 year return
- -75.61%
- 5 year return
- -68.35%
- 10 year return
- -
Last updated: 2025-04-08
DIVIDENDS
KA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | -3.29 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 12.26M |
| EPS (TTM) | -1.60 |
| FCF per share (TTM) | -0.73 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -4.34M |
| Gross profit (TTM) | -7.26M |
| Operating income (TTM) | -17.25M |
| Net income (TTM) | -20.88M |
| EPS (TTM) | -1.60 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 167.29% |
| Operating margin (TTM) | 397.67% |
| Profit margin (TTM) | 481.24% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 975.00K |
| Net receivables | 0.00 |
| Total current assets | 1.33M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 69.00K |
| Total assets | 1.40M |
| Accounts payable | 7.48M |
| Short/Current long term debt | 710.00K |
| Total current liabilities | 9.38M |
| Total liabilities | 9.38M |
| Shareholder's equity | -7.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.54M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -9.54M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -1492.21% |
| Return on Invested Capital | 290.43% |
| Cash Return on Invested Capital | 132.69% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.52 |
| Daily high | 0.52 |
| Daily low | 0.48 |
| Daily Volume | 5K |
| All-time high | 2814.00 |
| 1y analyst estimate | 13.50 |
| Beta | - |
| EPS (TTM) | -1.60 |
| Dividend per share | - |
| Ex-div date | 19 Dec 2022 |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| KA | S&P500 | |
| Current price drop from All-time high | -99.98% | -1.38% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 15 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -84.73% | -11.07% |
| Avg time to new high | 116 days | 12 days |
| Max time to new high | 2127 days | 1805 days |
COMPANY DETAILS
Marketcap
5.89M
Marketcap category
Small-cap
Description
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Employees
11
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner